IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: Concomitant results to a phase I/II study

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Brehm, Claudia ^a   Huenecke, Sabine ^a   Quaiser, Andrea ^a   Esser, Ruth ^a   Bremm, Melanie ^a   Kloess, Stephan ^a   Soerensen, Jan ^a   Kreyenberg, Hermann ^a   Seidl, Christian ^b   Becker, Petra S A ^b   Mühl, Heiko ^a   Klingebiel, Thomas ^a   Bader, Peter ^a   Passweg, Jakob R ^c   Schwabe, Dirk ^a   Koehl, Ulrike ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Institute for Transfusion Medicine and Immunohematology   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; CD69 ANTIGEN; FC RECEPTOR; L SELECTIN; LECTIN; LEUKOCYTE ANTIGEN; T LYMPHOCYTE ANTIGEN;

ADOLESCENT; ADOPTIVE TRANSFER; ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL ACTIVITY; CELL COUNT; CELL LOSS; CELL MIGRATION; CELL SELECTION; CELL STIMULATION; CELL TRANSFER; CHILD; CHIMERA; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIUM CELL; EX VIVO STUDY; EXTRAVASATION; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN CELL; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOREGULATION; IN VIVO STUDY; LEUKEMIA; LEUKEMIA REMISSION; LEUKOCYTE ADHERENCE; MALE; NATURAL KILLER CELL; NON INVASIVE PROCEDURE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCHOOL CHILD; STEM CELL; THERAPY EFFECT; TREATMENT DURATION; ADOPTIVE IMMUNOTHERAPY; CLINICAL TRIAL; DRUG EFFECT; IMMUNOLOGY; METABOLISM; METHODOLOGY;

ADOLESCENT; ADULT; ANTIGENS, CD; ANTIGENS, CD56; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CHILD; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; KILLER CELLS, NATURAL; L-SELECTIN; LECTINS, C-TYPE; LEUKEMIA; MALE; RECEPTORS, IGG; YOUNG ADULT;

EID: 80655128594     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027351     Document Type: Article

References (40)

1. Passweg JR, Koehl U, Uharek L, Meyer-Monard S, Tichelli A, (2006) Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation. Best Pract Res Clin Haematol 19: 811-824.
2. Passweg JR, Stern M, Koehl U, Uharek L, Tichelli A, (2005) Use of natural killer cells in hematopoetic stem cell transplantation. Bone Marrow Transplant 35: 637-643.
3. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, et al. (2010) NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 28: 955-959.
4. Lanier LL, (2005) NK cell recognition. Annu Rev Immunol 23: 225-274.
5. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, et al. (2001) Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 19: 197-223.
6. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA, (2002) Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 100: 1935-1947.
7. Ljunggren HG, Malmberg KJ, (2007) Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 7: 329-339.
8. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, et al. (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295: 2097-2100.
9. Cooper MA, Fehniger TA, Caligiuri MA, (2001) The biology of human natural killer-cell subsets. Trends Immunol 22: 633-640.
10. Dulphy N, Haas P, Busson M, Belhadj S, Peffault de Latour R, et al. (2008) An unusual CD56(bright) CD16(low) NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation. Journal of immunology 181: 2227-2237.
11. Nguyen S, Dhedin N, Vernant JP, Kuentz M, Al Jijakli A, et al. (2005) NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood 105: 4135-4142.
12. Koehl U, Sorensen J, Esser R, Zimmermann S, Gruttner HP, et al. (2004) IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis 33: 261-266.
13. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, et al. (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105: 3051-3057.
14. Passweg JR, Tichelli A, Meyer-Monard S, Heim D, Stern M, et al. (2004) Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 18: 1835-1838.
15. Rizzieri DA, Storms R, Chen DF, Long G, Yang Y, et al. (2010) Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 16: 1107-1114.
16. Huenecke S, Zimmermann SY, Kloess S, Esser R, Brinkmann A, et al. (2010) IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion. J Immunother 33: 200-210.
17. Koehl U, Bochennek K, Esser R, Brinkmann A, Quaritsch R, et al. (2008) ISHAGE-based single-platform flowcytometric analysis for measurement of absolute viable T cells in fresh or cryopreserved products: CD34/CD133 selected or CD3/CD19 depleted stem cells, DLI and purified CD56+CD3- NK cells. Int J Hematol 87: 98-105.
18. Koehl U, Esser R, Zimmermann S, Tonn T, Kotchetkov R, et al. (2005) Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children. Klin Padiatr 217: 345-350.
19. Zimmermann SY, Esser R, Rohrbach E, Klingebiel T, Koehl U, (2005) A novel four-colour flow cytometric assay to determine natural killer cell or T-cell-mediated cellular cytotoxicity against leukaemic cells in peripheral or bone marrow specimens containing greater than 20% of normal cells. J Immunol Methods 296: 63-76.
20. Huenecke S, Behl M, Fadler C, Zimmermann SY, Bochennek K, et al. (2008) Age-matched lymphocyte subpopulation reference values in childhood and adolescence: application of exponential regression analysis. Eur J Haematol 80: 532-539.
21. Becker S, Tonn T, Fussel T, Uhrberg M, Bogdanow M, et al. (2003) Assessment of killer cell immunoglobulinlike receptor expression and corresponding HLA class I phenotypes demonstrates heterogenous KIR expression independent of anticipated HLA class I ligands. Human immunology 64: 183-193.
22. Kreyenberg H, Holle W, Mohrle S, Niethammer D, Bader P, (2003) Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: the Tuebingen experience. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 17: 237-240.
23. Kloess S, Huenecke S, Piechulek D, Esser R, Koch J, et al. (2010) IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA. Eur J Immunol 40: 3255-3267.
24. Nishimura R, Baker J, Beilhack A, Zeiser R, Olson JA, et al. (2008) In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood 112: 2563-2574.
25. Olson JA, Zeiser R, Beilhack A, Goldman JJ, Negrin RS, (2009) Tissue-specific homing and expansion of donor NK cells in allogeneic bone marrow transplantation. Journal of immunology 183: 3219-3228.
26. Pegram HJ, Haynes NM, Smyth MJ, Kershaw MH, Darcy PK, (2010) Characterizing the anti-tumor function of adoptively transferred NK cells in vivo. Cancer immunology, immunotherapy: CII 59: 1235-1246.
27. Meller B, Frohn C, Brand JM, Lauer I, Schelper LF, et al. (2004) Monitoring of a new approach of immunotherapy with allogenic (111)In-labelled NK cells in patients with renal cell carcinoma. Eur J Nucl Med Mol Imaging 31: 403-407.
28. Nowak B, Weber C, Schober A, Zeiffer U, Liehn EA, et al. (2007) Indium-111 oxine labelling affects the cellular integrity of haematopoietic progenitor cells. Eur J Nucl Med Mol Imaging 34: 715-721.
29. Penack O, Gentilini C, Fischer L, Asemissen AM, Scheibenbogen C, et al. (2005) CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 19: 835-840.
30. Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, et al. (1985) In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. Journal of immunology 135: 2865-2875.
31. Salvo G, Samoggia P, Masciulli R, Boccoli G, Allavena P, et al. (1992) Interleukin-2 bolus therapy induces immediate and selective disappearance from peripheral blood of all lymphocyte subpopulations displaying natural killer activity: role of cell adhesion to endothelium. European journal of cancer 28A: 818-825.
32. Aronson FR, Libby P, Brandon EP, Janicka MW, Mier JW, (1988) IL-2 rapidly induces natural killer cell adhesion to human endothelial cells. A potential mechanism for endothelial injury. Journal of immunology 141: 158-163.
33. Siebert JC, Walker EB, (2010) Monitoring cytokine profiles during immunotherapy. Immunotherapy 2: 799-816.
34. Cassatella MA, (1995) The production of cytokines by polymorphonuclear neutrophils. Immunology today 16: 21-26.
35. Cassatella MA, Gasperini S, Calzetti F, Bertagnin A, Luster AD, et al. (1997) Regulated production of the interferon-gamma-inducible protein-10 (IP-10) chemokine by human neutrophils. European journal of immunology 27: 111-115.
36. Gardner L, Patterson AM, Ashton BA, Stone MA, Middleton J, (2004) The human Duffy antigen binds selected inflammatory but not homeostatic chemokines. Biochemical and biophysical research communications 321: 306-312.
37. Horne K, Woolley IJ, (2009) Shedding light on DARC: the role of the Duffy antigen/receptor for chemokines in inflammation, infection and malignancy. Inflammation research: official journal of the European Histamine Research Society [et al] 58: 431-435.
38. Schnabel RB, Baumert J, Barbalic M, Dupuis J, Ellinor PT, et al. (2010) Duffy antigen receptor for chemokines (Darc) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflammatory mediators. Blood 115: 5289-5299.
39. Middleton J, Patterson AM, Gardner L, Schmutz C, Ashton BA, (2002) Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood 100: 3853-3860.
40. Gregoire C, Chasson L, Luci C, Tomasello E, Geissmann F, et al. (2007) The trafficking of natural killer cells. Immunological reviews 220: 169-182.